COVID-19 Associated Coagulopathy in Egypt

Completed

• Conditions: Coagulopathy

• Registration Number: NCT04507230
• Lead Sponsor: Assiut University

Brief Summary

Coagulopathy is one of the most significant prognostic factors in patients with COVID-19 and is associated with increased mortality and admission to critical care. Most commonly observed coagulopathy in patients hospitalized with COVID-19 (COVID-19-associated coagulopathy) is characterized by increased D-dimer and fibrinogen levels. 71% of patients who did not survive hospitalization reported to have developed disseminated intravascular coagulation (DIC) compared to 0.6% of survivors.

Detailed Description

studying the detailed coagulation screen and second line coagulation parameters including both thrombophilia screen and other acute phase coagulation factors.

Study Timeline

• Study Start: 2020-08-07
• Study First Submitted: 2020-08-07
• Study First Submitted QC: 2020-08-07
• Study First Posted: 2020-08-11
• Primary Completion: 2020-10-31
• Study Completion: 2020-10-31
• Status Verified: 2021-03
• Last Update Submitted: 2021-03-10
• Last Update Posted: 2021-03-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 106

Inclusion Criteria

• patients with COVID 19 positive by RT- PCR

Exclusion Criteria

• no exclusions

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Coagulation screen	1 month	Full coagulation screen
Thrombophilia screen	1 month	Full thrombophilia screen
VWF, FVIII	1 month	VWFAg, FVIII

Trial Locations

Locations (1)

Assiut University Hospitals; 🇪🇬 Assiut, Egypt